Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2019 - 2026)

Mirum Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 13.58% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $25.1 million (up 4.37% YoY), while the FY2025 annual figure was $24.2 million, up 2.6% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $6.9 million, up from $6.1 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $6.9 million in Q1 2026, with the low at $342000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $5.7 million (2024), against an average of $4.0 million.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 1204.76% in 2022, then advanced 0.12% in 2025.
• Mirum Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.2 million in 2022, then surged by 357.45% to $5.5 million in 2023, then advanced by 10.23% to $6.1 million in 2024, then rose by 0.3% to $6.1 million in 2025, then rose by 13.17% to $6.9 million in 2026.
• Business Quant data shows MIRM's Depreciation & Amortization (CF) at $6.9 million in Q1 2026, $6.1 million in Q4 2025, and $6.1 million in Q3 2025.